Antibody-Mediated Rejection Prevention Market Set to Surge to USD 528.31 Million by 2033 at a 16% of CAGR, Driven by Advances in Complement Inhibition Therapies

The global antibody-mediated rejection (AMR) prevention market is poised for significant growth, with an anticipated valuation of US$ 89 million in 2023. According to recent market analysis, the sector is projected to expand at a remarkable compound annual growth rate (CAGR) of 16% from 2023 to 2033, ultimately reaching US$ 528.31 million by the end of the decade.

This growth is primarily driven by the increasing recognition of the complement system as a crucial component in the prevention of antibody-mediated rejection and the development of innovative therapies targeting this pathway.

Key Market Drivers:

• Rising Importance of the Complement System: Over the last decade, the complement system has gained prominence in the AMR prevention market. Its role in mediating immune responses and facilitating transplant acceptance makes it a focal point for therapeutic development.
• Focus on Complement Inhibitors: The primary goal of utilizing complement inhibitors is to prevent donor-specific antibody (DSA)-induced allograft damage. As research progresses and new therapies emerge, the demand for effective complement inhibitors is expected to drive market growth significantly.
• Increasing Transplantation Procedures: As the number of organ transplantation procedures continues to rise globally, there is an urgent need for effective AMR prevention strategies to enhance transplant outcomes and improve patient survival rates.

Regional Insights: North America is expected to dominate the antibody-mediated rejection prevention market, fueled by advanced healthcare infrastructure and robust investment in research and development. Europe is also projected to maintain a substantial share, while the Asia-Pacific region is anticipated to experience rapid growth due to increasing healthcare access and rising awareness of transplantation therapies.

Market Outlook: As advancements in complement inhibition therapies continue to evolve, the antibody-mediated rejection prevention market is well-positioned for impressive growth over the next decade. With a commitment to improving transplant outcomes and patient care, this market is set to thrive through 2033.

The citizenry with end-stage renal impairment is getting older. As in almost half of all new patient populations exceed the age of 65, and one-third are over the age of 70. As a consequence, late kidney transplant failure is pervasive in older people, which is anticipated to propel the antibody-mediated rejection prevention market over the coming years. According to a Pew Research Center report, the aged population in the United States will augment to 81 million by 2050, up from 37 million in 2005. As a result, this factor is expected to contribute to market expansion.

Key Takeaways from the Market Study

• The immunomodulators market is expected to grow at a CAGR of 6.3% over the forecast period.
• From 2018 to 2022, sales increased significantly at a CAGR of 14%.
• The global monoclonal antibodies segment was worth US$ 186 million in 2021
• The global monoclonal antibodies segment is expected to grow at a CAGR of 11% between 2023 and 2033.
• The global market for antibody-mediated rejection prevention is expected to be worth US$ 528.31 million.

“The population of people with end-stage kidney disease is getting older. Nearly half of all new patient populations are over 65, with one-third being over 70. As a result, late kidney transplant failure is common among the elderly, which is expected to drive the antibody-mediated rejection prevention market,” says the FMI analyst.

Key Market Players

Key players in the Antibody-mediated Rejection Prevention market are CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly, and Company, Bristol-Myers & Squibb Company. Some of the latest developments are below:

• Horizon Therapeutics plc disclosed in February 2021 that it will purchase Viela Bio, Inc. to substantially expand its product portfolio and flourish its rare disease medical portfolio.
• The trial’s Independent Data Monitoring Committee has recommended that the evaluation of Jardiance® (empagliflozin) in grownups with chronic kidney disease (CKD) be halted early. Following an official interim analysis that fulfilled predefined criteria for favorable efficacy, the Medical Research Council (MRC) Population Health Research Unit reported in March 2022.

Market Competition

Key players in the Antibody-mediated Rejection Prevention market are CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly, and Company, Bristol-Myers & Squibb Company. Some of the recent developments are below:

• Horizon Therapeutics plc revealed in February 2021 that it will procure Viela Bio, Inc. to significantly expand its product portfolio and thrive its rare disease medical portfolio.
• The trial’s Independent Data Monitoring Committee has recommended that the evaluation of Jardiance® (empagliflozin) in grownups with chronic kidney disease (CKD) be halted early. Following a formal interim evaluation that met prede?ned criteria for favorable efficacy, the Medical Research Council (MRC) Population Health Research Unit reported in March 2022.

Key Companies Profiled

• CSL Behring
• Hansa Biopharma
• Sanofi
• Talaris Therapeutics
• Horizon Therapeutics
• Novartis AG
• Biogen
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Bristol-Myers & Squibb Company

A Full Report Overview

Key Segments Profiled in the Antibody-mediated Rejection Prevention Market Survey

By Treatment:

• Monoclonal Antibodies
• Cysteine Protease Inhibitors
• Immunomodulators
• Plasmapheresis

By End User:

• Hospitals
• Specialty Clinics

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube